Investment Thesis
FONAR exhibits solid profitability metrics with 13.8% operating margins and 8.4% net margins, supported by fortress-like balance sheet strength with minimal debt and 10x current ratio. However, stagnant revenue growth (+1.4% YoY), deteriorating cash flow generation (negative FCF of -404K), and weak return metrics (2.4% ROE, 2.0% ROA) signal operational challenges despite financial stability.
Strengths
- Exceptional balance sheet strength with 176.9M equity, 53.0M cash, and effectively zero debt (7.0K LTD)
- Robust liquidity position with 10.0x current ratio and 9.80x quick ratio, providing significant financial flexibility
- Solid profitability metrics with 13.8% operating margin and 8.4% net margin in a medical device sector
- High interest coverage ratio of 106.3x demonstrates minimal financial distress risk
Risks
- Anemic revenue growth at only 1.4% YoY indicates potential market saturation or competitive headwinds in medical imaging
- Negative free cash flow of -404K despite 4.3M net income suggests capital intensity exceeds earnings generation
- Weak return on equity (2.4%) and return on assets (2.0%) indicate inefficient capital deployment despite large asset base of 217.2M
- Operating cash flow of 1.9M significantly lags net income of 4.3M, raising earnings quality concerns
Key Metrics to Watch
- Revenue growth acceleration - critical to justify investment case
- Free cash flow trend - must return to positive to validate earnings sustainability
- Return on equity and ROA improvement - capital efficiency is primary concern
- Operating cash flow to net income ratio - monitor earnings quality deterioration
Financial Metrics
Revenue
51.6M
Net Income
4.3M
EPS (Diluted)
$1.16
Free Cash Flow
-404.0K
Total Assets
217.2M
Cash
53.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
13.8%
Net Margin
8.4%
ROE
2.4%
ROA
2.0%
FCF Margin
-0.8%
Balance Sheet & Liquidity
Current Ratio
10.00x
Quick Ratio
9.80x
Debt/Equity
0.00x
Debt/Assets
25.0%
Interest Coverage
106.33x
Long-term Debt
7.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-25T05:06:11.899566 |
Data as of: 2025-12-31 |
Powered by Claude AI